Safebridge consultants inc
This presentation is the property of its rightful owner.
Sponsored Links
1 / 28

SafeBridge Consultants, Inc. PowerPoint PPT Presentation


  • 527 Views
  • Uploaded on
  • Presentation posted in: General

Risk-MaPP Quality & IH Implications. Robert Sussman, Ph.D., DABT Managing Principal, Eastern Operations John P. Farris, CIH President & CEO Pharmaceutical IH Forum – May 18, 2011 Some slides courtesy of ISPE and PharmaConsult US. SafeBridge Consultants, Inc. Product Quality Applications.

Download Presentation

SafeBridge Consultants, Inc.

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Safebridge consultants inc

Risk-MaPP

Quality & IH Implications

Robert Sussman, Ph.D., DABT

Managing Principal, Eastern Operations

John P. Farris, CIH

President & CEO

Pharmaceutical IH Forum – May 18, 2011

Some slides courtesy of ISPE and PharmaConsult US

SafeBridge Consultants, Inc.


Product quality applications

Product Quality Applications


Causes of cross contamination

Causes of Cross-Contamination

  • Mix-up

    • Wrong ingredient in wrong equipment/batch

  • Retention

    • Inadequate cleaning

  • Mechanical transfer

    • Moving residue from one place/device to another

  • Airborne transfer

    • Airborne powders can contact product or product contact surfaces


Current guidance ich q7a fda 2001

Current Guidance – ICH Q7A (FDA 2001)

  • “The use of dedicated production areas should also be considered when material of an infectious nature or high pharmacological activity or toxicity is involved (e.g., certain steroids or cytotoxic anti-cancer agents) unless validated inactivation and/or cleaning procedures are established and maintained.”

  • Similar language in Canadian, European, and Brazilian regulations.

    • certain antibiologics, certain hormones, certain highly active drugs


Highly hazardous compounds

Highly Hazardous Compounds

  • Adapted from the NIOSH Hazardous Drug Alert

    • Genotoxic compounds that are known or likely to be carcinogenic to humans

    • Compounds that can produce reproductive and/or developmental effects at low dosages

    • Compounds that can produce serious target organ toxicity or other significant adverse effects at low dosages

  • “for which validated cleaningor inactivation procedures cannot be established (e.g., the acceptable level of residue is below the limit of detection by the best available analytical methods).”


Approaches to establishing cleaning limits

Approaches to Establishing Cleaning Limits

  • 1/1000 of the low clinical dose – May be over-protective or under-protective, depending on the data set

  • LD50/50,000 – May be over-protective or under-protective, depending on the data set

  • 10 ppm– Arbitrary GMP-based value permits carryover based on potency of subsequent product

  • 100 µg/swab – Upper limit to ensure visual cleanliness (VRL – Visual Residue Limit)

  • No standard, prescribed approach

  • Above methods are NOT science- or risk-based


History

History

  • June 2005 ISPE Meeting

    • FDA thinking of requiring “potent” or “hazardous” compounds to be segregated similar to penicillins

    • Big Pharma representatives discussed alternatives

    • Several speakers invited to present approach at FDA

  • January 2006 – presentation to FDA

    • How to set ADEs

    • Exposure assessments

    • Flexible approaches to containment

    • Cleaning validation

  • FDA very supportive of ISPE’s Guideline approach & wanted to be involved in development


Risk based ma nufacturing of p harmaceutical p roducts

Risk-Based Manufacturing of Pharmaceutical Products

HAZARD

QUALITY

CONTROL

RISK


What is risk mapp

What is Risk-MaPP?

  • Risk-MaPP provides a scientific, risk-based approach based on ICH Q9 for setting health-based cross-contamination and cleaning validation limits

  • These limits drive the risk controls that are implemented on a case-by-case basis to maintain product quality

  • Engineering controls may reduce airborne dust and obviate the need for segregation

    • Dedication / segregation always remain an option, but should not be seen as precedent-setting


Ich q9 quality risk management

ICH Q9 - Quality Risk Management

Risk Identification

Systematic use of information to identify hazards.

Risk Analysis

Estimation of risk associated with identified hazards.

Risk Review

Risk Evaluation

Comparison of analyzed risk against given risk criteria.

Risk Control

Decision making to reduce and/or accept risks.


Concepts of a risk based approach

Concepts of a Risk-Based Approach

  • Hazard is an inherent property of a drug

  • Zero risk not scientifically achievable or necessary

  • Risk = (Hazard X Exposure)

    • Hazard is fixed

    • Exposure can be controlled

  • High Hazard does not necessarily mean high Risk

  • Use a consistent, robust, science-based approach

  • Make decisions case-by-case, not by class

  • Control risk by methods other than segregation


  • Establishing health based limits acceptable daily exposure ade

    Establishing Health-Based Limits:Acceptable Daily Exposure (ADE)

    • Define a daily dose of a substance, below which no adverse effects are anticipated, even if exposure occurs over a lifetime:

  • Identify the critical endpoint (most sensitive clinically significant health effect)

  • Define the No-observed-adverse-effect level (NOAEL) or Lowest-OAEL (LOAEL)

  • Consider sources of uncertainty and choose appropriate “safety factor(s)”

  • Calculate an ADE for that route of exposure


  • Calculating an ade

    Calculating an ADE

    ADE (mg/day) = NOAEL (mg/kg/day) x BW (kg)

    UFC x MF

    where:

    NOAEL = No-observed-adverse-effect level

    BW = Body weight

    UFC = Composite uncertainty factor(s)

    MF = Modifying factor


    Threshold of toxicological concern ttc

    Threshold of Toxicological Concern (TTC)

    • Compounds likely to be carcinogenic

      ADE = 1 µg/day

    • Compounds likely to be potentor highly-toxic

      ADE = 10 µg/day

    • Compounds NOTlikely to be potent, highly toxic, or genotoxic

      ADE = 100 µg/day

    Provides guidance for unstudied compounds that fall into one of three categories:

    Dolan DG, Naumann BD, Sargent EV, Maier A, Dourson M Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations. Regul. Tox. Pharm. 43:1-9 (2005)


    Application of ade

    Application of ADE

    • Calculate maximum allowable carry-over (MACO) from one product to another

      (Parenteral Drug Association cleaning guidance, 1992)

    • Calculate cleaning limit for product contact surfaces based on surface area, batch size, and dose of the next drug


    Compound a

    Compound A

    • Opioid Analgesic

    • LD50 = 10,000 mg/kg

      • Lowest Clinical Dose (LCD) = 10 mg/day

        • UFC = 30

        • MF = 3

      • ADE = (10 mg/day)/(30 x 3) = 100 µg/day


    Compound b

    Compound B

    • Genotoxic antineoplastic agent

    • LD50 = 3,400 mg/kg

      • LCD = 70 mg/day

      • ADE = 1 µg/day

        • TTC


    Comparison to other limits

    Comparison to Other Limits


    Ade caveats

    ADE Caveats

    • An ADE is for patient use and may need to include sensitive subgroups (elderly, children) that are not considered in developing an OEL

    • An ADE is NOT equal to the OEL x 10 m3

      • May use same data set, but different safety factors and bioavailability data may be applied

      • Consider sensitive sub-populations

      • Consider bioavailability by the route of administration


    Fda s response to risk mapp

    FDA’s Response to Risk-MaPP

    • “… the firm’s rationale for the residue limits established should be logical … and be practical, achievable, and verifiable…”

    • “Check the manner in which limits are established… The objective of the inspection is to ensure that the basis for any limit is scientifically justifiable.”

    • “Encourage implementation of risk-based approaches that focus both industry and Agency attention on critical areas…”

    • “Ensure that regulatory review, compliance, and inspection policies are based on state-of-the-art pharmaceutical science.”


    Industrial hygiene applications

    Industrial Hygiene Applications


    Industrial hygiene applications1

    Industrial Hygiene Applications

    • Traditionally IH tools have not been accepted for quality determination purposes

    • Risk-MaPP incorporates basic safety elements of risk assessment and risk management used for decades

    • Air monitoring studies now requested by regulatory inspectors in EU and FDA

      • Sterile fill/finish company

      • Generics company

      • Specialty Device CMO

      • API CMO


    Air sampling factors

    Air Sampling Factors

    • Some drug agency regulators:

      • Interested in personal sampling and demonstration of health protective environment; and

      • Interested in quality and prevention of releases out of primary process rooms

    • Other drug agency regulators:

      • Interested only in detection of materials in adjacent areas


    Industrial hygiene air monitoring

    Industrial Hygiene Air Monitoring

    • IH monitoring data intended to be compared to health-based limits

    • Limits of detection of sampling & analytical methods should be based on health limits (OELs, PELs, TLVs etc.)

    • Methods must be validated for air monitoring

      • Samples stable in air streams

      • Volume limitations determined

      • Device types and samples extraction procedures established

    • Sampling plan should be established prior to survey

      • Include personal and area samples to answer particular questions


    Issues with air monitoring and quality

    Issues with Air Monitoring and Quality

    • Air samples may be indicative of a potential to impact product quality

      • Not proof

    • Interpretation of data without limits established in advance

      • Method sensitivity may not be appropriate

      • Quantitative results must be compared to something

      • Detection does not equal risk

    • Inherent limitations of monitoring

      • +/- 25% accuracy

      • Number of samples required to determine confidence


    Surrogate monitoring results clinical scale operations g m 3

    Surrogate Monitoring Results:Clinical Scale Operations (µg/m3)


    Api monitoring results g m 3

    API Monitoring Results (µg/m3)

    Testing and release process inside ventilated enclosure


    Summary

    Summary

    • Quality audits should review cleaning validation programs

    • Cleaning limits should be health-protective, i.e.:

      • Based on the ADE developed by toxicologists

      • Using well-established methodology

      • From data in regulatory filings or the open literature

    • Air monitoring is a useful indicator of potential for release of material

      • Designed for occupational health determinations

      • May be used as one aspect of product quality and assist with case for multiproduct facilities

    • Interpretation of that data is dependant on a number of factors

    • Be careful what you ask for!


  • Login